An update on RNA interference-mediated gene silencing in cancer therapy

Bibliography

• Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci USA 1998;95:15502-7
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Lieberman J. Knocking down disease with siRNAs. Cell 2006;126:231-5
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8
   PubMed Web of Science ®Google Scholar
• Giladi H, Ketzinel-Gilad M, Rivkin L, et al. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003;8:769-76
   PubMed Web of Science ®Google Scholar
• Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004;10:816-20
   PubMed Web of Science ®Google Scholar
• Yang WQ, Zhang Y. RNAi-mediated gene silencing in cancer therapy. Expert Opin Biol Ther 2012;12:1495-504
   PubMed Web of Science ®Google Scholar
• Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-5
   PubMed Web of Science ®Google Scholar
• Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009;137:1032-46
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-52
   PubMed Web of Science ®Google Scholar
• Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010;103:1617-26
   PubMed Web of Science ®Google Scholar
• Park JK, Kogure T, Nuovo GJ, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011;71:7608-16
   PubMed Web of Science ®Google Scholar
• Callegari E, Elamin BK, Giannone F, et al. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012;56:1025-33
   PubMed Web of Science ®Google Scholar
• Liu P, Qi M, Ma C, et al. Let7a inhibits the growth of endometrial carcinoma cells by targeting Aurora-B. FEBS Lett 2013;587:2523-9
   PubMed Web of Science ®Google Scholar
• Zhang H, Luo XQ, Feng DD, et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia. Mol Cancer 2011;10:108
   PubMed Web of Science ®Google Scholar
• Rai D, Kim SW, McKeller MR, et al. Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis. Proc Natl Acad Sci USA 2010;107:3111-16
   PubMed Web of Science ®Google Scholar
• Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 2007;282:2130-4
   PubMed Web of Science ®Google Scholar
• Fazi F, Rosa A, Fatica A, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005;123:819-31
   PubMed Web of Science ®Google Scholar
• Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429:457-63
   PubMed Web of Science ®Google Scholar
• Scott GK, Mattie MD, Berger CE, et al. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006;66:1277-81
   PubMed Web of Science ®Google Scholar
• Mattick JS, Amaral PP, Dinger ME, et al. RNA regulation of epigenetic processes. Bioessays 2009;31:51-9
   PubMed Web of Science ®Google Scholar
• Li CH, Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol 2013;45:1895-910
   PubMed Web of Science ®Google Scholar
• Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol 2011;21:354-61
   PubMed Web of Science ®Google Scholar
• Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol 2011;22:366-76
   PubMed Web of Science ®Google Scholar
• Orom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010;143:46-58
   PubMed Web of Science ®Google Scholar
• Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011;10:38
   PubMed Web of Science ®Google Scholar
• Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 2010;19:R152-61
   PubMed Web of Science ®Google Scholar
• Liu Y, Pan S, Liu L, et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS One 2012;7:e35145
   PubMed Web of Science ®Google Scholar
• Lai MC, Yang Z, Zhou L, et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol 2012;29:1810-16
   PubMed Web of Science ®Google Scholar
• Schmidt LH, Spieker T, Koschmieder S, et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J Thorac Oncol 2011;6:1984-92
   PubMed Web of Science ®Google Scholar
• Tano K, Mizuno R, Okada T, et al. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 2010;584:4575-80
   PubMed Web of Science ®Google Scholar
• Ying L, Chen Q, Wang Y, et al. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 2012;8:2289-94
   PubMed Web of Science ®Google Scholar
• Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013;32:1616-25
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhou L, Wu LM, et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol 2011;18:1243-50
   PubMed Web of Science ®Google Scholar
• Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010;464:1071-6
   PubMed Web of Science ®Google Scholar
• Geng YJ, Xie SL, Li Q, et al. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res 2011;39:2119-28
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70
   PubMed Web of Science ®Google Scholar
• Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3:406-17
   PubMed Web of Science ®Google Scholar
• Leenders F, Mopert K, Schmiedeknecht A, et al. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J 2004;23:3303-13
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B, Traugott U, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther 2012;50:76-8
   PubMed Web of Science ®Google Scholar
• Greenberger LM, Horak ID, Filpula D, et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008;7:3598-608
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-94
   PubMed Web of Science ®Google Scholar
• Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65
   PubMed Web of Science ®Google Scholar
• Hart SL. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol Toxicol 2010;26:69-81
   PubMed Web of Science ®Google Scholar
• Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J 2009;11:639-52
   PubMed Web of Science ®Google Scholar
• McNamara JO II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-15
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-14
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Campani V, Misso G, et al. In vivo activity of MiR-34a mimics delivered by stable nucleic acid lipid Particles (SNALPs) against multiple myeloma. PLoS One 2014;9:e90005
   PubMed Web of Science ®Google Scholar
• Costa PM, Cardoso AL, Mendonca LS, et al. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment. Mol Ther Nucleic Acids 2013;2:e100
   PubMedGoogle Scholar
• Wagner E, Zenke M, Cotten M, et al. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 1990;87:3410-14
   PubMed Web of Science ®Google Scholar
• Li X, Stuckert P, Bosch I, et al. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells. Cancer Gene Ther 2001;8:555-65
   PubMed Web of Science ®Google Scholar
• Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-48
   PubMed Web of Science ®Google Scholar
• Ge YL, Zhang JY, Zhang X, et al. Chemically modified siRNA directed against the KDR gene inhibits the proliferation of breast cancer cells. Mol Med Rep 2009;2:121-7
   Web of Science ®Google Scholar
• Wu SY, Yang X, Gharpure KM, et al. 2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 2014;5:3459
   PubMed Web of Science ®Google Scholar
• Hall K, Blair Zajdel ME, Blair GE. Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochem J 2010;431:321-36
   Google Scholar
• Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther 2010;18:477-90
   PubMed Web of Science ®Google Scholar
• Sun A, Tang J, Terranova PF, et al. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study. Int J Cancer 2010;126:764-74
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang F, Cai H, et al. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. J Gene Med 2008;10:518-26
   PubMed Web of Science ®Google Scholar
• Tietze R, Lyer S, Durr S, et al. Efficient drug-delivery using magnetic nanoparticles – biodistribution and therapeutic effects in tumour bearing rabbits. Nanomedicine 2013;9:961-71
   PubMed Web of Science ®Google Scholar
• Guo W, Chen W, Yu W, et al. Small interfering RNA-based molecular therapy of cancers. Chin J Cancer 2013;32:488-93
   PubMedGoogle Scholar
• Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-7
   PubMed Web of Science ®Google Scholar
• Tschuch C, Schulz A, Pscherer A, et al. Off-target effects of siRNA specific for GFP. BMC Mol Biol 2008;9:60
   Google Scholar
• Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 2005;33:4527-35
   PubMed Web of Science ®Google Scholar
• Heine M, Freund B, Nielsen P, et al. High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes. PLoS One 2012;7:e36258
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81
   PubMed Web of Science ®Google Scholar
• Drummond DC, Noble CO, Guo Z, et al. Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release 2010;141:13-21
   PubMed Web of Science ®Google Scholar
• Caffrey DR, Zhao J, Song Z, et al. siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS One 2011;6(7):e21503
   PubMed Web of Science ®Google Scholar
• Birmingham A, Anderson EM, Reynolds A, et al. 3’ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3:199-204
   PubMed Web of Science ®Google Scholar
• Chen X, Liu P, Chou HH. Whole-genome thermodynamic analysis reduces siRNA off-target effects. PLoS One 2013;8:e58326
   PubMedGoogle Scholar
• Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008;19:111-24
   PubMed Web of Science ®Google Scholar
• Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-7
   PubMed Web of Science ®Google Scholar
• Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006;13:494-505
   PubMed Web of Science ®Google Scholar
• Audouy SA, de Leij LF, Hoekstra D, Molema G. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002;19:1599-605
   PubMed Web of Science ®Google Scholar
• Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. Int J Pharm 2009;367:195-203
   PubMed Web of Science ®Google Scholar
• Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: an update review. Curr Pharm Des 2009;15:2724-50
   PubMed Web of Science ®Google Scholar
• Raemdonck K, Naeye B, Hogset A, et al. Biodegradable dextran nanogels as functional carriers for the intracellular delivery of small interfering RNA. J Control Release 2010;148:e95-6
   PubMed Web of Science ®Google Scholar
• Gunther M, Lipka J, Malek A, et al. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 2011;77:438-49
   PubMed Web of Science ®Google Scholar
• Ortiz Mellet C, Garcia Fernandez JM, Benito JM. Cyclodextrin-based gene delivery systems. Chem Soc Rev 2011;40:1586-608
   PubMed Web of Science ®Google Scholar
• George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan – a review. J Control Release 2006;114:1-14
   PubMed Web of Science ®Google Scholar
• Susa M, Iyer AK, Ryu K, et al. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PLoS One 2010;5:e10764
   PubMed Web of Science ®Google Scholar